Literature DB >> 23467713

Mosaic Trisomy 21 and Trisomy 14 as Acquired Cytogenetic Abnormalities without GATA1 Mutation in A Pediatric Non-Down Syndrome Acute Megakaryoblastic Leukemia.

Yi Xiao1, Jia Wei, Jin-Huan Xu, Jian-Feng Zhou, Yi-Cheng Zhang.   

Abstract

One case of acute megakaryoblastic leukemia (AMKL) with trisomy 21, trisomy 14 and unmutated GATA1 gene in a phenotypically normal girl was reported. The patient experienced transient myelodysplasia before the onset of AMKL. The bone marrow blasts manifested typical morphology of megakaryoblast both by the May-Giemsa staining and under the electronic microscopy. Leukemic cells were positive for CD13, CD33, CD117, CD56, CD38, CD41 and CD61 in flow cytometry analysis. Cytogenetic study showed karyotype of 48, XX, +14, +21 in 40% metaphases. Known mutations of GATA1 gene in Down syndrome or acquired trisomy 21 were not detected in this case.

Entities:  

Keywords:  Acute megakaryoblastic leukemia; Cytogenetics; GATA1; Myelodysplasia

Year:  2011        PMID: 23467713      PMCID: PMC3587565          DOI: 10.1007/s11670-011-0239-4

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  15 in total

1.  Comprehensive analysis of gene alterations in acute megakaryoblastic leukemia of Down's syndrome.

Authors:  Y Hirose; K Kudo; H Kiyoi; Y Hayashi; T Naoe; S Kojima
Journal:  Leukemia       Date:  2003-11       Impact factor: 11.528

2.  Down syndrome and GATA1-related transient leukemia.

Authors:  Claudio Sandoval; Sharon R Pine
Journal:  J Pediatr       Date:  2007-03       Impact factor: 4.406

Review 3.  Acute megakaryoblastic leukemia after transient myeloproliferative disorder with clonal karyotype evolution in a phenotypically normal neonate.

Authors:  Jacek M Polski; Csaba Galambos; Gordon B Gale; Cherie H Dunphy; H Lance Evans; Jacqueline R Batanian
Journal:  J Pediatr Hematol Oncol       Date:  2002-01       Impact factor: 1.289

4.  GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.

Authors:  Johann K Hitzler; Joseph Cheung; Yue Li; Stephen W Scherer; Alvin Zipursky
Journal:  Blood       Date:  2003-02-13       Impact factor: 22.113

5.  Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.

Authors:  Joshua Wechsler; Marianne Greene; Michael A McDevitt; John Anastasi; Judith E Karp; Michelle M Le Beau; John D Crispino
Journal:  Nat Genet       Date:  2002-08-12       Impact factor: 38.330

Review 6.  GATA1-related leukaemias.

Authors:  Ritsuko Shimizu; James Douglas Engel; Masayuki Yamamoto
Journal:  Nat Rev Cancer       Date:  2008-04       Impact factor: 60.716

7.  Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome.

Authors:  Asahito Hama; Hiroshi Yagasaki; Yoshiyuki Takahashi; Nobuhiro Nishio; Hideki Muramatsu; Nao Yoshida; Makito Tanaka; Hirokazu Hidaka; Nobuhiro Watanabe; Ayami Yoshimi; Kimikazu Matsumoto; Kazuko Kudo; Koji Kato; Keizo Horibe; Seiji Kojima
Journal:  Br J Haematol       Date:  2008-03       Impact factor: 6.998

8.  Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome.

Authors:  Diane C Cabelof; Hiral V Patel; Qing Chen; Holly van Remmen; Larry H Matherly; Yubin Ge; Jeffrey W Taub
Journal:  Blood       Date:  2009-07-24       Impact factor: 22.113

9.  ERG is a megakaryocytic oncogene.

Authors:  Samira Salek-Ardakani; Gil Smooha; Jasper de Boer; Neil J Sebire; Michelle Morrow; Liat Rainis; Sandy Lee; Owen Williams; Shai Izraeli; Hugh J M Brady
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

Review 10.  Tetrasomy 21 as a sole acquired abnormality without GATA1 gene mutation in pediatric acute megakaryoblastic leukemia: a case report and review of the literature.

Authors:  Myung-Geun Shin; Hyun-Woo Choi; Hye-Ran Kim; Mi-Ji Kim; Hee-Jo Baek; Dong-Kyun Han; Hoon Kook; Tai-Ju Hwang; Hyoung-Joon Kim; Soo-Hyun Kim; Jong-Hee Shin; Soon-Pal Suh; Dong-Wook Ryang
Journal:  Leuk Res       Date:  2008-03-26       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.